Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer

NCT00005025 is registered in ClinicalTrials.gov with John Stoddard Cancer Center at Iowa Methodist Medical Center as lead sponsor.

NCT NCT00005025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer
Lead sponsor
John Stoddard Cancer Center at Iowa Methodist Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer